WO2014087217A1 - Allogenic mesendritic vector for ovarian cancer - Google Patents
Allogenic mesendritic vector for ovarian cancer Download PDFInfo
- Publication number
- WO2014087217A1 WO2014087217A1 PCT/IB2013/002684 IB2013002684W WO2014087217A1 WO 2014087217 A1 WO2014087217 A1 WO 2014087217A1 IB 2013002684 W IB2013002684 W IB 2013002684W WO 2014087217 A1 WO2014087217 A1 WO 2014087217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- mesenchymal stem
- stem cells
- dendritic cells
- dendritic
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 24
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 19
- 206010033128 Ovarian cancer Diseases 0.000 title claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 63
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 52
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 239000000427 antigen Substances 0.000 claims abstract description 27
- 102000036639 antigens Human genes 0.000 claims abstract description 27
- 108091007433 antigens Proteins 0.000 claims abstract description 27
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 15
- 230000001413 cellular effect Effects 0.000 abstract description 9
- 238000013459 approach Methods 0.000 abstract description 4
- 238000003306 harvesting Methods 0.000 abstract description 3
- 229940030156 cell vaccine Drugs 0.000 abstract description 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 5
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101001001271 Mus musculus Prostatic acid phosphatase Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 210000004409 osteocyte Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 208000004434 Calcinosis Diseases 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012303 cytoplasmic staining Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 1
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101001035657 Rattus norvegicus 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011892 Von Kossa's method Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 108010042408 dexamethasone receptor Proteins 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Definitions
- the present invention relates to the technology of progenitor and immune privileged cells and its clinical application in filing a solution for ovarian cancers, more particularly belongs to the method of preparing a novel pharmaco-cellular composition comprising mesenchymal and dendritic cells as cellular vectors in treating ovarian cancers.
- Ovarian cancer is a type of solid tumour that begins in the ovaries. Ovarian cancer symptoms are mistaken for more-common conditions and so with late diagnosis, cure is not possible.
- the treatment of ovarian cancer is based on the stage of the disease which is a reflection of the extent or spread of the cancer to other parts of the body. The stages of cancer are explained as below:
- Stage I If the cancer is confined to one or both ovaries.
- Stage II If either one or both of the ovaries are involved and the tumour has spread to the uterus and/or the fallopian tubes or other sites in the pelvis.
- Stage III If one or both of the ovaries are involved and the tumour has spread to lymph nodes or other sites such as outside the pelvis region but is still within the abdominal cavity, such as the surface of the intestine or liver.
- Stage IV If one or both ovaries are involved and the tumour has spread outside the abdomen or has spread to the inside of the liver.
- Immune system has the potential to eliminate neoplastic cells. Escape from immune surveillance is believed to be a fundamental biological feature of malignant disease in man, which contributes to uncontrolled tumour growth, eventually leading to death of the host. Defects in immune response in patients with a variety of tumours and in tumour-bearing animals have been well documented. The key element is the induction of the anti-cancer immune response, namely Tumor Associated Antigens (TAAg) presentation to T cells in a tumour-bearing host (human and animal).
- TAAg Tumor Associated Antigens
- Bone marrow-derived Antigen Presenting Cells were shown to play an important role in the presentation of TAAgs, a function previously assigned predominantly to tumour cells. Therefore, elucidation of the role of such APCs, in particular Dendritic Cells (DCs) helped to better understand the mechanisms underlying anti-tumour immune responses and, improve the effectiveness of anti-cancer immunity in tumour-bearing hosts.
- Dendritic cells are Antigen Presenting Cells (APCs) which play a critical role in the regulation of the adaptive immune response. Dendritic cells (DCs) are unique and have been referred to as "professional" APCs.
- DCs The principal function of DCs is to present antigens; only DCs have the ability to induce a primary immune response in resting na ' ive T lymphocytes. To perform this function, DCs capture antigens, process them, and present them on the cell surface along with appropriate co-stimulatory molecules. DCs also play a role in the maintenance of B cell function and recall responses. Thus, DCs are critical in the establishment of immunological memory. The unique ability of DCs to activate na ' ive and memory CD4+ and CD8+ T cells suggests that they could be used for the induction of a specific antitumour immunity. In the past few years, several in vitro and in vivo studies in rodents and humans have demonstrated that immunizations with DCs pulsed with tumour antigens resulted in protective immunity and rejection of established tumours in various malignancies.
- Ovarian cancer precursors originating from the bone marrow, migrate to virtually every organ in the body, where immature DCs take up the surrounding antigens. After antigen uptake, the DCs mature, co-stimulatory molecules (e.g., CD40, CD80, CD86) are up regulated and the DCs migrate to the lymphoid tissues where they activate effector T cells. Consequently, tumour antigen- loaded DCs may be ideal cells for the generation and amplification of antitumour responses in a vaccination setting.
- Several clinical studies have shown distinct clinical responses after vaccination with tumour antigen-loaded, autologous DCs. Despite these successes, the only problem remaining is limited number of DCs available for immunotherapy.
- DCs are not only important for the initiation of specific cytotoxic T cell (CTL) responses, but also for the maintenance of protective CTL, it may be crucial to repeatedly vaccinate cancer patients with tumor antigen-loaded DCs.
- CTL cytotoxic T cell
- mDCs myeloid dendritic cells derived in vitro suppressed angiogenesis in vivo through production of interleukin 12, implicating the role of mDCs in tumour pathology.
- the therapeutic implications of recent findings state that specific myeloid cell populations of dendritic cells modulate the responses of tumours to agents such as chemotherapy and some anti-angiogenic therapies.
- MSCs Mesenchymal stem cells targeted to cancers are expected to contribute many soluble factors such as mitogens, extracellular matrix proteins, angiogenic and inflammatory factors, as well as exosomes with as yet poorly defined potentials, once resident in the Tumour Micro Environment (TME). MSCs are also expected to affect tumour-associated leukocytes either directly by cell-cell contact or indirectly by the secretion of trophic factors. MSCs are known to affect the proliferation and differentiation of dendritic cells, monocytes/macrophages, B and T cells, NK cells, and even mast cells. There has been a great deal of debate in the field in trying to assert the role of MSCs in anti-tumour mechanisms.
- Ovarian cancer treatment usually involves surgery, chemotherapy and autologous dendritic cell therapy.
- the primary one is surgery at which time the cancer is removed from the ovary and from as many other sites as is possible.
- Chemotherapy is the second important modality which uses drugs to kill the cancer cells.
- the other modality is radiation treatment, which is used in only certain instances. It utilizes high energy x-rays to kill cancer cells.
- Second look surgery and Salvage chemotherapy are the other treatment options to address recurrent types of ovarian cancers.
- High-dose chemotherapy accompanied with Autologous Bone Marrow Transplantation (ABMT) and Peripheral Blood Stem Cell transplantation (PBSCT) produces high response rates (70-82%) in patients with resistance to primary chemotherapy, but the responses are generally of limited duration.
- This invention uses mouse prostatic acid phosphatase (mPAP) which can be used as a xenogeneic antigen to induce prostate-directed immunity in other malian species.
- the vehicles that are used for this induction include viruses such as vaccinia virus or dendritic cells which express mPAP, human PAP or rat PAP.
- US Patent 6210662 entitled “Immunostimulatory composition” discloses an invention which is directed to a therapeutic composition for stimulating a cellular immune response.
- the novel composition disclosed is an isolated, stimulated potent antigen presenting cell such as activated dendritic cell that can activate T-cells to produce a multivalent cellular immune response against a selected antigen.
- the potent antigen presenting cells are stimulated by exposing them in vitro to a polypeptide complex which is essentially of a dendritic cell-binding protein and a polypeptide antigen.
- US Patent 6194152 entitled "Prostate tumour polynucleotide compositions and methods of detection thereof provides chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides. It also provides a method for producing the polypeptides disclosed above, as are detection assays that detect the presence of tumour cells in tissue or bodily fluid samples and a method for identifying novel compositions which modulate the activity of prostate tumour antigens and the use of such compositions in diagnosis and treatment of disease.
- US Patent Application 20100055076 entitled “Mesenchymal stem cell-mediated autologous dendritic cells with increased immune suppression” describes a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses that has an enhanced potential to suppress immune responses can be utilized for treating various diseases.
- the composition as disclosed in the present invention was prepared/ adopted in treating the tumour has always been for autologous applications with autologous preparations and compositions.
- the dendritic cells were postulated to target the tumours with loaded antigens and there are not many global groups working on dendritic cell vaccines which adopt the properties of mesenchymal stem cells for ovarian cancer treatment. Allogenic dendritic cells - mesenchymal stem cells combination (Mesendritic) as the vector in targeted ovarian cancer treatment is innovative concept in cancer therapeutics.
- a novel composition administered as vector in treating ovarian cancer comprising dendritic special type and mesenchymal stem cells harvested in allogenic donated cord blood source that are primed with patient's tumour antigens.
- the present invention also discloses a method for preparing a novel composition as specified above.
- the novelty of the invention resides in the mixture used which is human cord blood derived allogenic mesenchymal stem cells and allogenic dendritic cells. Both the cell types in the presence of each other would affect the surface marker profiles on each type to benefit the composition to neutralize the unwanted immune-stimulation post allogenic infusion while targeting tumour zone with no immune suppression prescribed in the treatment.
- the technology exploits the properties of mesenchymal stem cells and dendritic cells in killing the targeted tumour cells benefiting the patient with no further morbidity of either bone marrow or peripheral blood aspirations for obtaining higher yields of either therapeutic dendritic cells or mesenchymal stem cells.
- Figure 1 shows a flowchart illustrating the method of preparation of the vector composition
- Figure 2 shows the collected cord blood stored in a sterile collection bag
- FIG. 3 shows the cultured mesenchymal stem cells at Passage 1(P1) and Passage 3(P3);
- Figure 4 shows a table illustrating the comparative expressions of surface markers on mesenchymal stem cells at Passage 0 (PO) and Passage (P3) harvested and expanded from the cord blood source (Thali R - Image based cytometer data);
- Figure 5 shows cultured mesenchymal stem cells at P3 showing cytoplasmic staining of TIMP- i;
- Figure 6 shows the results of PO mesenchymal stem cells trans-differentiated in-vitro wherein 6A shows the phase contrast mesenchymal stem cells micrpgraph (10X); 6B shows Von Kossa stained calcium deposits in mesenchymal stem cells differentiated to osteocytes culture; 6C shows Oil-O-Red stained adipocytes; and 6D shows Alcian blue stained chondrocyte cellular cluster;
- 6A shows the phase contrast mesenchymal stem cells micrpgraph (10X)
- 6B shows Von Kossa stained calcium deposits in mesenchymal stem cells differentiated to osteocytes culture
- 6C shows Oil-O-Red stained adipocytes
- 6D shows Alcian blue stained chondrocyte cellular cluster
- Figure 7 shows the micrograph (10X) of MACS segregated and seeded dendritic cells from cord blood.
- Figure 8A shows the micrograph (10X) of the mixture of mesenchymal stem cells and dendritic cells at 1 :1 ratio;
- Figure 8B shows 98% viability of the same mixture stained with Propidium Iodide;
- Figure 8C is a representative photograph of 22% of cells testing positive for cytoplasmic stained green color with FITC conjugated secondary antibody against TIMP-1 antibody.
- the present invention discloses a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers.
- the treatment technology proposed is a combination of adult immune privileged mesenchymal stem cells and antigen presenting dendritic cells especially myeloid dendritic cells as the cellular vectors primed to targeted killing of tumour cells.
- the unique source of cellular derivatives i.e. human umbilical cord blood is one of it's kind and is shown to reside naive and unmanipulated cellular population with therapeutic values attributed.
- the abundant allogenic donated cord blood source is used to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient's tumour antigens for a targeted treatment regime.
- dendritic cells and mesenchymal stem cells in immunomodulation are exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient's body.
- the source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application.
- the main advantage of this composition to treat ovarian cancers will not subject the suffering patients for any longer waiting for dendritic cells to be cultured as in for autologous preparations and also for a culture independent yield used as cellular formulation for clinical applications.
- the process of the immune privileged Mesendritic therapeutic vector and the clinical application modality are proprietary in nature of the technology proposed.
- the present invention describes a novel composition that can used as vaccines for treating ovarian cancer comprising mesenchymal stem cells and antigen presenting myeloid dendritic cells obtained from an allogenic source of cord blood primed with antigens obtained from autologous tumour cells and a method of preparing vaccines that includes allogenic mesenchymal stem cells and dendritic cells primed with antigens obtained from the autologous tumour cells as referred in Figure 1.
- both the mesenchymal stem cells and antigen presenting dendritic cells are isolated from the allogenic blood source.
- the Umbilical Cord Blood samples are collected from full-term delivery cases with previous consent from the mothers according to the Institute's ethical and scientific committee guidelines.
- Figure 2 shows the collected cord blood stored in a sterile collection bag.
- Preparation of Mesenchymal Stem Cells 50 ml aliquots of the collected cord blood from the bag is aspirated out in sterile 50 ml syringes to centrifuge using percoll gradient separation method for buffy coat containing mononuclear cells (MNCs) separation.
- MNCs mononuclear cells
- the 3 ml of buffy coat obtained after centrifugation was suspended in proliferation medium consisting of DMEM-F12 (Gibo, Life Technologies, Carlsbad, CA, USA) with 20% FBS (GIBCO, USA), 20ng/ml fibroblast growth factor (FGF)-2 (Chemicon, Millipore, Billerica, MA, USA), 1% penicillin/streptomycin (Gibco) and was plated in T25 flasks at a density of 5 x 106 cells/ml.
- proliferation medium consisting of DMEM-F12 (Gibo, Life Technologies, Carlsbad, CA, USA) with 20% FBS (GIBCO, USA), 20ng/ml fibroblast growth factor (FGF)-2 (Chemicon, Millipore, Billerica, MA, USA), 1% penicillin/streptomycin (Gibco) and was plated in T25 flasks at a density of 5 x 106 cells/ml.
- the adherent cells obtained at P0 and P3 harvested and expanded from the cord blood source are analyzed for the expressions of surface markers namely CD34, CD90, CD 105, HLA-ABC with image cell cytometry (Thali R , Invitrogen, USA).
- Figure 4 shows a table illustrating the comparative expressions of surface markers on mesenchymal stem cells at P0 and P3 harvested and expanded from the cord blood source (Thali R - Image based cytometer data).
- mesenchymal stem cells at P0 and P3 are found to show variation in the surface marker expression percentages although no significance is attributed to any factor. Therefore, P0 and P3 mesenchymal stem cells are two different cell populations in terms of the composition expressing varied surface markers and the cell cycle state.
- Mesenchymal stem cells at P0 and P3 are stained with anti-TIMP-1 antibody (Abeam; 1 :200); FITC conjugated secondary antibody. Immunofluorescence of the cells as observed, shows more than 15% of the number of cells test positive for TIMP-1 expression at P0 compared to P3 cells as shown in Figure 5 which shows cultured mesenchymal stem cells at P3 showing cytoplasmic staining of TIMP-1. The positively stained green cells are counted per focus of 100 cells and an average of five foci is compared between PO and P3 cultures.
- FIG. 6 shows the results of PO mesenchymal stem cells trans-differentiated in-vitro wherein 6A shows the phase contrast mesenchymal stem cells - micrpgraph (10X); 6B shows Von Kossa stained calcium deposits in the mesenchymal stem cells differentiated to osteocytes culture; 6C shows Oil-O-Red stained adipocytes; and 6D shows Alcian blue stained chondrocytic cellular cultures. .
- Dendritic Cells suitable for administration to subjects can be isolated or obtained from the allogenic cord blood source by culturing and harvesting using standard techniques known in the prior art. 2X10 9 cells (adjusted with Normal Saline, 10ml), of Cord blood collected in the bag is prepared for mDCs isolation using myeloid dendritic cell isolation kit (MACS Miltenyi Biotech, Germany). Figure 7 shows the micrograph (10X) of MACS segregated and seeded dendritic cells from cord blood.
- Mesenchymal stem cells at P0 and P3 are mixed in different pre-determined ratios with the myeloid dendritic cells (cell density ratios).
- Table 1 shows the different compositions of the vector cell base that can be prepared and named accordingly.
- MD1 mixture is enumerated under the microscope and stained with Propidium Iodide (PI) to assess the viability. More than 98% of the cell mixture is recorded to be viable with only 2% of the cells stained red with PI.
- the cell mixture (1ml) is seeded in growth medium containing DMEM-F12 and 10% FBS for overnight in a coated tissue culture plate. After 16 hours of sedimentation of the cells in the plate, the cells are fixed in paraformaldehyde (4%) and stained with anti-human TIMP-1 antibody. The Immunofluorescence of the cells showed 20-22% more cells test positive for cytoplasmic stained green color with FITC conjugated secondary antibody.
- Figure 8 A shows the photograph of the mesenchymal stem cells and dendritic cells mixture at 1:1 ratio; Figure 8B shows 98% viability of the same mixture stained with Propidium Iodide; and Figure 8C shows the photograph of 22% of cells, testing positive for cytoplasmic stained green color with FITC conjugated secondary antibody against TIMP-1 primary antibody.
- the biopsy (1-2 inches) of the tumor tissue obtained is macerated in a sterile container and the cell suspension in cell proliferation medium. 50-100 cells of the biopsy counted under the microscope is mixed with the vector cell based ratios as shown in Table 2.
- Example 2 Tumor cell line ATCC IGROV1 cultured in RPMI 1640 supplented with 10% Fetal Bovine Serum is sub cultured for 7 days. Cells are trypsinized and washed with the growth medium. Upto 200 cells counted in the growth medium is mixed with MD1 tube cells at room temperature. The stability of the vector prepared is checked for every one hour till 10 hrs of incubation at 37° C with 5% C0 2 by evaluating the apoptosis.
- Zhao X Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumours with whole tumour cell lysate-pulsed dendritic cells. Immunol Invest 2001;30:33-45. [PubMed: 11419910]
- VEGF vascular endothelial growth factor
Abstract
The present invention recommends a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers. It proposes the abundant allogenic donated cord blood source to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient's tumour antigens for a targeted treatment regime. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient's body. The source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application.
Description
ALLOGENIC MESENDRITIC VECTOR FOR OVARIAN CANCER
FIELD OF THE INVENTION
The present invention relates to the technology of progenitor and immune privileged cells and its clinical application in filing a solution for ovarian cancers, more particularly belongs to the method of preparing a novel pharmaco-cellular composition comprising mesenchymal and dendritic cells as cellular vectors in treating ovarian cancers.
BACKGROUND AND PRIOR ART
Ovarian cancer is a type of solid tumour that begins in the ovaries. Ovarian cancer symptoms are mistaken for more-common conditions and so with late diagnosis, cure is not possible. The treatment of ovarian cancer is based on the stage of the disease which is a reflection of the extent or spread of the cancer to other parts of the body. The stages of cancer are explained as below:
Stage I: If the cancer is confined to one or both ovaries.
Stage II: If either one or both of the ovaries are involved and the tumour has spread to the uterus and/or the fallopian tubes or other sites in the pelvis.
Stage III: If one or both of the ovaries are involved and the tumour has spread to lymph nodes or other sites such as outside the pelvis region but is still within the abdominal cavity, such as the surface of the intestine or liver.
Stage IV: If one or both ovaries are involved and the tumour has spread outside the abdomen or has spread to the inside of the liver.
Autologous Dendritic Cell Potency to activate the naive T- cells of Immune system to treat tumour related malignant diseases is a revolutionary medical treatment approach. Immune system has the potential to eliminate neoplastic cells. Escape from immune surveillance is believed to be a fundamental biological feature of malignant disease in man, which contributes to uncontrolled tumour growth, eventually leading to death of the host. Defects in immune response
in patients with a variety of tumours and in tumour-bearing animals have been well documented. The key element is the induction of the anti-cancer immune response, namely Tumor Associated Antigens (TAAg) presentation to T cells in a tumour-bearing host (human and animal). Bone marrow-derived Antigen Presenting Cells (APCs) were shown to play an important role in the presentation of TAAgs, a function previously assigned predominantly to tumour cells. Therefore, elucidation of the role of such APCs, in particular Dendritic Cells (DCs) helped to better understand the mechanisms underlying anti-tumour immune responses and, improve the effectiveness of anti-cancer immunity in tumour-bearing hosts. Dendritic cells are Antigen Presenting Cells (APCs) which play a critical role in the regulation of the adaptive immune response. Dendritic cells (DCs) are unique and have been referred to as "professional" APCs. The principal function of DCs is to present antigens; only DCs have the ability to induce a primary immune response in resting na'ive T lymphocytes. To perform this function, DCs capture antigens, process them, and present them on the cell surface along with appropriate co-stimulatory molecules. DCs also play a role in the maintenance of B cell function and recall responses. Thus, DCs are critical in the establishment of immunological memory. The unique ability of DCs to activate na'ive and memory CD4+ and CD8+ T cells suggests that they could be used for the induction of a specific antitumour immunity. In the past few years, several in vitro and in vivo studies in rodents and humans have demonstrated that immunizations with DCs pulsed with tumour antigens resulted in protective immunity and rejection of established tumours in various malignancies.
Ovarian cancer precursors, originating from the bone marrow, migrate to virtually every organ in the body, where immature DCs take up the surrounding antigens. After antigen uptake, the DCs mature, co-stimulatory molecules (e.g., CD40, CD80, CD86) are up regulated and the DCs migrate to the lymphoid tissues where they activate effector T cells. Consequently, tumour antigen- loaded DCs may be ideal cells for the generation and amplification of antitumour responses in a vaccination setting. Several clinical studies have shown distinct clinical responses after vaccination with tumour antigen-loaded, autologous DCs. Despite these successes, the only problem remaining is limited number of DCs available for immunotherapy. As DCs are not only
important for the initiation of specific cytotoxic T cell (CTL) responses, but also for the maintenance of protective CTL, it may be crucial to repeatedly vaccinate cancer patients with tumor antigen-loaded DCs. Studies reported that myeloid dendritic cells (mDCs) derived in vitro suppressed angiogenesis in vivo through production of interleukin 12, implicating the role of mDCs in tumour pathology. The therapeutic implications of recent findings state that specific myeloid cell populations of dendritic cells modulate the responses of tumours to agents such as chemotherapy and some anti-angiogenic therapies.
Mesenchymal stem cells (MSCs) targeted to cancers are expected to contribute many soluble factors such as mitogens, extracellular matrix proteins, angiogenic and inflammatory factors, as well as exosomes with as yet poorly defined potentials, once resident in the Tumour Micro Environment (TME). MSCs are also expected to affect tumour-associated leukocytes either directly by cell-cell contact or indirectly by the secretion of trophic factors. MSCs are known to affect the proliferation and differentiation of dendritic cells, monocytes/macrophages, B and T cells, NK cells, and even mast cells. There has been a great deal of debate in the field in trying to assert the role of MSCs in anti-tumour mechanisms.
Ovarian cancer treatment usually involves surgery, chemotherapy and autologous dendritic cell therapy. The primary one is surgery at which time the cancer is removed from the ovary and from as many other sites as is possible. Chemotherapy is the second important modality which uses drugs to kill the cancer cells. The other modality is radiation treatment, which is used in only certain instances. It utilizes high energy x-rays to kill cancer cells. Second look surgery and Salvage chemotherapy are the other treatment options to address recurrent types of ovarian cancers. High-dose chemotherapy accompanied with Autologous Bone Marrow Transplantation (ABMT) and Peripheral Blood Stem Cell transplantation (PBSCT) produces high response rates (70-82%) in patients with resistance to primary chemotherapy, but the responses are generally of limited duration. Such approaches are generally limited to clinical trials, and are also being tested for first line therapy. Autologous dendritic cell therapy is being practiced as experimental personalized therapy addressing relapsed/refractory types. This service involves the patient's own immune system to kill the cancer cells. These immune cells are called dendritic cells that
are monocytes and are harvested from patient's blood. The dendritic cells are cultured in a special classified laboratory, formulated into a vaccine using the patient's own tumour cells. US Patent 7414108 entitled "Composition and method for producing an immune response against tumour-related antigens" discloses a novel composition and a method for producing an immune response that is directed against a tumour- related antigen. This invention uses mouse prostatic acid phosphatase (mPAP) which can be used as a xenogeneic antigen to induce prostate-directed immunity in other mamalian species. The vehicles that are used for this induction include viruses such as vaccinia virus or dendritic cells which express mPAP, human PAP or rat PAP.
US Patent 6210662 entitled "Immunostimulatory composition" discloses an invention which is directed to a therapeutic composition for stimulating a cellular immune response. The novel composition disclosed is an isolated, stimulated potent antigen presenting cell such as activated dendritic cell that can activate T-cells to produce a multivalent cellular immune response against a selected antigen. The potent antigen presenting cells are stimulated by exposing them in vitro to a polypeptide complex which is essentially of a dendritic cell-binding protein and a polypeptide antigen.
US Patent 6194152 entitled "Prostate tumour polynucleotide compositions and methods of detection thereof provides chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides. It also provides a method for producing the polypeptides disclosed above, as are detection assays that detect the presence of tumour cells in tissue or bodily fluid samples and a method for identifying novel compositions which modulate the activity of prostate tumour antigens and the use of such compositions in diagnosis and treatment of disease.
US Patent Application 20100055076 entitled "Mesenchymal stem cell-mediated autologous dendritic cells with increased immune suppression" describes a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses that has an enhanced potential to suppress immune responses can be utilized for treating various diseases.
The composition as disclosed in the present invention was prepared/ adopted in treating the tumour has always been for autologous applications with autologous preparations and compositions. The dendritic cells were postulated to target the tumours with loaded antigens and there are not many global groups working on dendritic cell vaccines which adopt the properties of mesenchymal stem cells for ovarian cancer treatment. Allogenic dendritic cells - mesenchymal stem cells combination (Mesendritic) as the vector in targeted ovarian cancer treatment is innovative concept in cancer therapeutics. SUMMARY
A novel composition administered as vector in treating ovarian cancer comprising dendritic special type and mesenchymal stem cells harvested in allogenic donated cord blood source that are primed with patient's tumour antigens. The present invention also discloses a method for preparing a novel composition as specified above. The novelty of the invention resides in the mixture used which is human cord blood derived allogenic mesenchymal stem cells and allogenic dendritic cells. Both the cell types in the presence of each other would affect the surface marker profiles on each type to benefit the composition to neutralize the unwanted immune-stimulation post allogenic infusion while targeting tumour zone with no immune suppression prescribed in the treatment. The technology exploits the properties of mesenchymal stem cells and dendritic cells in killing the targeted tumour cells benefiting the patient with no further morbidity of either bone marrow or peripheral blood aspirations for obtaining higher yields of either therapeutic dendritic cells or mesenchymal stem cells. BRIEF DESCRIPTION OF THE DRAWINGS
For a more complete understanding of example embodiments of the present technology, reference is now made to the following descriptions taken in connection with the accompanying drawings in which:
Figure 1 shows a flowchart illustrating the method of preparation of the vector composition; Figure 2 shows the collected cord blood stored in a sterile collection bag;
Figure 3 shows the cultured mesenchymal stem cells at Passage 1(P1) and Passage 3(P3);
Figure 4 shows a table illustrating the comparative expressions of surface markers on mesenchymal stem cells at Passage 0 (PO) and Passage (P3) harvested and expanded from the cord blood source (ThaliR- Image based cytometer data); Figure 5 shows cultured mesenchymal stem cells at P3 showing cytoplasmic staining of TIMP- i;
Figure 6 shows the results of PO mesenchymal stem cells trans-differentiated in-vitro wherein 6A shows the phase contrast mesenchymal stem cells micrpgraph (10X); 6B shows Von Kossa stained calcium deposits in mesenchymal stem cells differentiated to osteocytes culture; 6C shows Oil-O-Red stained adipocytes; and 6D shows Alcian blue stained chondrocyte cellular cluster;
Figure 7 shows the micrograph (10X) of MACS segregated and seeded dendritic cells from cord blood; and
Figure 8A shows the micrograph (10X) of the mixture of mesenchymal stem cells and dendritic cells at 1 :1 ratio; Figure 8B shows 98% viability of the same mixture stained with Propidium Iodide; and Figure 8C is a representative photograph of 22% of cells testing positive for cytoplasmic stained green color with FITC conjugated secondary antibody against TIMP-1 antibody.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present technology. It will be apparent, however, to the one skilled in the art that the present technology can be practiced without these specific details.
Reference in this specification to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present technology. The appearance of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments. Moreover, various features are described which may be exhibited by some embodiments and not by others. Similarly, various requirements are described which may be required for some embodiments but not other embodiments. Moreover, although the following description contains many specifics for the purposes- of illustration, anyone skilled in the art will appreciate that many variations and/or alterations to said details are within the scope of the present technology. Similarly, although many of the features of the present technology are described in terms of each other, or in conjunction with each other, one skilled in the art will appreciate that many of these features can be provided independently of other features. Accordingly, this description of the present technology is set forth without any loss of generality to, and without imposing limitations upon, the present technology.
The present invention discloses a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers. The treatment technology proposed is a combination of adult immune privileged mesenchymal stem cells and antigen presenting dendritic cells especially myeloid dendritic cells as the cellular vectors primed to targeted killing of tumour cells. The unique source of cellular derivatives i.e. human umbilical cord blood is one of it's kind and is shown to reside naive and unmanipulated cellular population with therapeutic values attributed.
The abundant allogenic donated cord blood source is used to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient's tumour antigens for a targeted treatment regime. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient's body. The source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application. The main advantage of this composition to treat ovarian cancers will not subject the suffering patients for any longer waiting for dendritic cells to be cultured as in for autologous preparations and also for a culture independent yield used as cellular formulation for clinical applications.
The process of the immune privileged Mesendritic therapeutic vector and the clinical application modality are proprietary in nature of the technology proposed. The present invention describes a novel composition that can used as vaccines for treating ovarian cancer comprising mesenchymal stem cells and antigen presenting myeloid dendritic cells obtained from an allogenic source of cord blood primed with antigens obtained from autologous tumour cells and a method of preparing vaccines that includes allogenic mesenchymal stem cells and dendritic cells primed with antigens obtained from the autologous tumour cells as referred in Figure 1.
In the present invention, both the mesenchymal stem cells and antigen presenting dendritic cells are isolated from the allogenic blood source. In one of the embodiment of the invention, the Umbilical Cord Blood samples are collected from full-term delivery cases with previous consent from the mothers according to the Institute's ethical and scientific committee guidelines. Figure 2 shows the collected cord blood stored in a sterile collection bag.
Preparation of Mesenchymal Stem Cells:
50 ml aliquots of the collected cord blood from the bag is aspirated out in sterile 50 ml syringes to centrifuge using percoll gradient separation method for buffy coat containing mononuclear cells (MNCs) separation. The 3 ml of buffy coat obtained after centrifugation was suspended in proliferation medium consisting of DMEM-F12 (Gibo, Life Technologies, Carlsbad, CA, USA) with 20% FBS (GIBCO, USA), 20ng/ml fibroblast growth factor (FGF)-2 (Chemicon, Millipore, Billerica, MA, USA), 1% penicillin/streptomycin (Gibco) and was plated in T25 flasks at a density of 5 x 106 cells/ml.
After 24 hours of incubation at 37°C with 5% C02; the non-adherent cells were washed off and the cells that were attached to the flask were cultured further with medium being replenished every alternate day. The adherent fibroblastic cell type once confluent in the flask (Passage 0, P0) is trypsinized to next passages for expansion of the cells, thrice (Passage 3, P3). Figure 3 shows the cultured mesenchymal stem cells at Passage 1 (PI) and Passage 3 (P3). The adherent cells obtained at P0 and P3 harvested and expanded from the cord blood source are analyzed for the expressions of surface markers namely CD34, CD90, CD 105, HLA-ABC with image cell cytometry (ThaliR, Invitrogen, USA).
Figure 4 shows a table illustrating the comparative expressions of surface markers on mesenchymal stem cells at P0 and P3 harvested and expanded from the cord blood source (ThaliR- Image based cytometer data). With reference to the figure 4, mesenchymal stem cells at P0 and P3 are found to show variation in the surface marker expression percentages although no significance is attributed to any factor. Therefore, P0 and P3 mesenchymal stem cells are two different cell populations in terms of the composition expressing varied surface markers and the cell cycle state.
Mesenchymal stem cells at P0 and P3 (70-80% confluent as shown in figure 3) are stained with anti-TIMP-1 antibody (Abeam; 1 :200); FITC conjugated secondary antibody. Immunofluorescence of the cells as observed, shows more than 15% of the number of cells test positive for TIMP-1 expression at P0 compared to P3 cells as shown in Figure 5 which shows cultured mesenchymal stem cells at P3 showing cytoplasmic staining of TIMP-1. The positively
stained green cells are counted per focus of 100 cells and an average of five foci is compared between PO and P3 cultures.
Trans-differentiation of the PO and P3 mesenchymal stem cells in-vitro showed that both the cultures are equally able to become osteocytes, chondrocytes and adipocytes with positive staining for vonkossa, alcain blue and oil-o-red chemicals. Figure 6 shows the results of PO mesenchymal stem cells trans-differentiated in-vitro wherein 6A shows the phase contrast mesenchymal stem cells - micrpgraph (10X); 6B shows Von Kossa stained calcium deposits in the mesenchymal stem cells differentiated to osteocytes culture; 6C shows Oil-O-Red stained adipocytes; and 6D shows Alcian blue stained chondrocytic cellular cultures. .
Preparation of Antigen Presenting Dendritic Cells:
Dendritic Cells suitable for administration to subjects can be isolated or obtained from the allogenic cord blood source by culturing and harvesting using standard techniques known in the prior art. 2X109 cells (adjusted with Normal Saline, 10ml), of Cord blood collected in the bag is prepared for mDCs isolation using myeloid dendritic cell isolation kit (MACS Miltenyi Biotech, Germany). Figure 7 shows the micrograph (10X) of MACS segregated and seeded dendritic cells from cord blood.
Preparation of cell based vector:
Mesenchymal stem cells at P0 and P3 are mixed in different pre-determined ratios with the myeloid dendritic cells (cell density ratios). Table 1 shows the different compositions of the vector cell base that can be prepared and named accordingly.
Table 1
4 (P0 + PI) (50:50) 1 MD4
Example 1
MD1 mixture is enumerated under the microscope and stained with Propidium Iodide (PI) to assess the viability. More than 98% of the cell mixture is recorded to be viable with only 2% of the cells stained red with PI. The cell mixture (1ml) is seeded in growth medium containing DMEM-F12 and 10% FBS for overnight in a coated tissue culture plate. After 16 hours of sedimentation of the cells in the plate, the cells are fixed in paraformaldehyde (4%) and stained with anti-human TIMP-1 antibody. The Immunofluorescence of the cells showed 20-22% more cells test positive for cytoplasmic stained green color with FITC conjugated secondary antibody. Figure 8 A shows the photograph of the mesenchymal stem cells and dendritic cells mixture at 1:1 ratio; Figure 8B shows 98% viability of the same mixture stained with Propidium Iodide; and Figure 8C shows the photograph of 22% of cells, testing positive for cytoplasmic stained green color with FITC conjugated secondary antibody against TIMP-1 primary antibody.
Preparation of vector and its composition:
The biopsy (1-2 inches) of the tumor tissue obtained is macerated in a sterile container and the cell suspension in cell proliferation medium. 50-100 cells of the biopsy counted under the microscope is mixed with the vector cell based ratios as shown in Table 2.
Table 2
Example 2: Tumor cell line ATCC IGROV1 cultured in RPMI 1640 supplented with 10% Fetal Bovine Serum is sub cultured for 7 days. Cells are trypsinized and washed with the growth medium. Upto 200 cells counted in the growth medium is mixed with MD1 tube cells at room temperature. The stability of the vector prepared is checked for every one hour till 10 hrs of incubation at 37° C with 5% C02 by evaluating the apoptosis. Till 10th hour of the incubation, there was no abnormal apoptosis observed by Image cytometer using annexin V marker in the preparation establishing the stability of the mixture of cells in the presence of each other presenting as cell based vector candidacy for allogenic infusion targeting the solid tumor tissue.
References:
1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Rev Cancer 2009;9:167-81. [PubMed: 19238149]
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. [PubMed: 18287387]
3. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of tumour-specific HLA class I- restricted CD8+ cytotoxic T lymphocytes by ovarian tumour antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601-9. [PubMed: 10992180]
4. Santin AD, Bellone S, Ravaggi A, et al. Induction of ovarian tumour-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol
2000;96:422-30. [PubMed: 10960637]
5. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumours with whole tumour cell lysate-pulsed dendritic cells. Immunol Invest 2001;30:33-45. [PubMed: 11419910]
6. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce anti-tumour immunity. J Immunol 2000;165:1705-1 1. [PubMed: 10903782]
7. Chiang CLL, Ledermann JA, Rad AN, et al. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumour cells by dendritic cells to cross-prime tumour-specific T cells. Cancer Immunol Immunother 2006;55: 1384-95. [PubMed: 16463039]
8. Hernando JJ, Park TW, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51 :45-52. [PubMed: 11845259] 9. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004;16:87-92. [PubMed: 15128013]
10. Aggarwal, S. & Pittenger, M.F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, Vol.105, pp 1815 - 1822, ISSN 0006-4971, doi: 10.1182/blood- 2004-04-1559
11. Barleon, B. et al. (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood, Vol.87, pp 3336 - 3343, ISSN 0006-4971
12. Bian, Z-Y. et al. (2010). Human mesenchymal stem cells promote growth of osteosarcoam : Involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. , Vol.101 , pp 2554 - 2560, doi: 10.1 11 1/j.1349-7006.2010.01731.x 13. Bisping, G. et al. (2009). Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4 ;14) myeloma. Clin. Cancer Res., Vol.15, pp 520 - 531, doi: 10.1158/1078-0432.CCR-08- 1612.
14. www.clinicaltrials.gov
Claims
1. A method of preparing a novel pharmaco-cellular composition to be administered into the patient's body as vector for treating solid tumors comprising the steps of:
a. collecting blood sample from an allogenic donor in a sterile collection bag;
b. preparing stable, viable, expressive and differentiable mesenchymal stem cells;
c. preparing stable dendritic cells from the collected blood sample;
d. mixing the mesenchymal stem cells and the dendritic cells at a pre-determined ratio to form a cell based vector; and
e. mixing the said cell based vector with a pre-determined quantity of isolated autologous tumor cells essentially containing tumor cell antigen at specific condition.
2. The method o Claim 1 where preparing stable, viable, expressive and differentiable mesenchymal stem cells further comprising the steps of:
a. isolating mesenchymal stem cells from the collected blood sample;
b. culturing and expanding the mesenchymal stem cells serially in a growth medium;
c. analyzing the mesenchymal stem cells obtained at Passage 0 (P0) and Passage 3 (P3) of its expansion for their ability to express surface markers; and
d. conducting trans-differentiation experiments on the P0 and P3 mesenchymal stem cells in vitro.
3. The method of Claim 1 wherein preparing the cell based vector further comprising the steps of: a. mixing the P0 and P3 mesenchymal stem cells at a ratio of 50:50; and
b. mixing the obtained mesenchymal stem cells with the isolated dendritic cells at different pre- determined cell density ratio to get different samples of cell based vector.
4. The method of Claim 1 wherein mixing the said cell based vector with a pre-determined quantity of isolated autologous tumor cells further comprises of mixing the cell based vector with 50-200 tumour cells essentially consisting of tumor antigen at room temperature and evaluating its apoptosis.
5. The method of Claim 1 wherein it is used for treating solid tumors including ovarian cancer.
6. The method of Claim 1 wherein the dendritic cells are the myeloid dendritic cells derived from the collected blood sample.
7. A novel pharmaco-cellular composition to be administered in to the patient's body as vector for . treating solid tumors as immediately as possible without any delay as in autologous preparation, primarily comprising of allogenic stable and expressive mesenchymal stem cells and allogenic special type dendritic cells in equilibrated package, primed with autologous patient's tumour antigens for a targeted treatment regime.
8. The novel pharmaco-cellular composition of Claim 7 wherein the dendritic cells are the myeloid dendritic cells derived from the collected blood sample.
9. The novel pharmaco-cellular composition of Claim 7 wherein it is used in treating solid tumors including ovarian cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/649,212 US10022402B2 (en) | 2012-12-03 | 2013-12-02 | Allogenic mesendritic vector for ovarian cancer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN5030CH2012 | 2012-12-03 | ||
| IN5030/CHE/2012 | 2012-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014087217A1 true WO2014087217A1 (en) | 2014-06-12 |
Family
ID=49955396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2013/002684 WO2014087217A1 (en) | 2012-12-03 | 2013-12-02 | Allogenic mesendritic vector for ovarian cancer |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US10022402B2 (en) |
| WO (1) | WO2014087217A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017167959A1 (en) * | 2016-04-01 | 2017-10-05 | Apceth Gmbh & Co. Kg | Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194152B1 (en) | 1997-08-20 | 2001-02-27 | Dendreon Corporation | Prostate tumor polynucleotide compositions and methods of detection thereof |
| US6210662B1 (en) | 1995-12-28 | 2001-04-03 | Dendreon Corporation | Immunostimulatory composition |
| US7414108B2 (en) | 1997-04-11 | 2008-08-19 | Dendreon Corporation | Composition and method for producing an immune response against tumor-related antigens |
| WO2008102937A1 (en) * | 2007-02-22 | 2008-08-28 | Creagene Inc. | Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression |
-
2013
- 2013-12-02 US US14/649,212 patent/US10022402B2/en not_active Expired - Fee Related
- 2013-12-02 WO PCT/IB2013/002684 patent/WO2014087217A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210662B1 (en) | 1995-12-28 | 2001-04-03 | Dendreon Corporation | Immunostimulatory composition |
| US7414108B2 (en) | 1997-04-11 | 2008-08-19 | Dendreon Corporation | Composition and method for producing an immune response against tumor-related antigens |
| US6194152B1 (en) | 1997-08-20 | 2001-02-27 | Dendreon Corporation | Prostate tumor polynucleotide compositions and methods of detection thereof |
| WO2008102937A1 (en) * | 2007-02-22 | 2008-08-28 | Creagene Inc. | Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression |
| US20100055076A1 (en) | 2007-02-22 | 2010-03-04 | Creagene Inc. | Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression |
Non-Patent Citations (19)
| Title |
|---|
| AGGARWAL, S.; PITTENGER, M.F.: "Human mesenchymal stem cells modulate allogeneic immune cell responses", BLOOD, vol. 105, 2005, pages 1815 - 1822 |
| B. ZHANG ET AL: "Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population", BLOOD, vol. 113, no. 1, 2 October 2008 (2008-10-02), pages 46 - 57, XP055104004, ISSN: 0006-4971, DOI: 10.1182/blood-2008-04-154138 * |
| BARLEON, B ET AL.: "Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1", BLOOD, vol. 87, 1996, pages 3336 - 3343 |
| BIAN, Z-Y. ET AL.: "Human mesenchymal stem cells promote growth of osteosarcoam : Involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2", CANCER SCI., vol. 101, pages 2554 - 2560 |
| BISPING, G. ET AL.: "Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4 ;14) myeloma", CLIN. CANCER RES., vol. 15, pages 520 - 531 |
| CANNON MJ; SANTIN AD; O'BRIEN TJ: "Immunological treatment of ovarian cancer", CURR OPIN OBSTET GYNECOL, vol. 16, 2004, pages 87 - 92 |
| CHIANG CLL; LEDERMANN JA; RAD AN ET AL.: "Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumour cells by dendritic cells to cross-prime tumour-specific T cells", CANCER IMMUNOL IMMUNOTHER, vol. 55, 2006, pages 1384 - 95 |
| ENGLISH K ET AL: "Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 115, no. 1, 15 January 2008 (2008-01-15), pages 50 - 58, XP026863356, ISSN: 0165-2478, [retrieved on 20071031] * |
| GONG J ET AL: "FUSIONS OF HUMAN OVARIAN CARCINOMA CELLS WITH AUTOLOGOUS OR ALLOGENEIC DENDRITIC CELLS INDUCE ANTITUMOR IMMUNITY", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 3, 1 August 2000 (2000-08-01), pages 1705 - 1711, XP001000988, ISSN: 0022-1767 * |
| GONG J; NIKRUI N; CHEN D ET AL.: "Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce anti-tumour immunity", J IMMUNOL, vol. 165, 2000, pages 1705 - 11 |
| HERNANDO JJ; PARK TW; KUBLER K ET AL.: "Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial", CANCER IMMUNOL IMMUNOTHER, vol. 51, 2002, pages 45 - 52 |
| I HUS ET AL: "Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia", LEUKEMIA, vol. 19, no. 9, 30 June 2005 (2005-06-30), pages 1621 - 1627, XP055104093, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2403860 * |
| JEMAL A; SIEGEL R; WARD E ET AL.: "Cancer statistics", CA CANCER J CLIN, vol. 58, 2008, pages 71 - 96 |
| RALF HASS ET AL: "Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment", CELL COMMUNICATION AND SIGNALING, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 3 September 2012 (2012-09-03), pages 26, XP021116117, ISSN: 1478-811X, DOI: 10.1186/1478-811X-10-26 * |
| S. CHIESA ET AL: "Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 42, 29 September 2011 (2011-09-29), pages 17384 - 17389, XP055103984, ISSN: 0027-8424, DOI: 10.1073/pnas.1103650108 * |
| SANTIN AD; BELLONE S; RAVAGGI A ET AL.: "Induction of ovarian tumour-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells", OBSTET GYNECOL, vol. 96, 2000, pages 422 - 30 |
| SANTIN AD; HERMONAT PL; RAVAGGI A ET AL.: "Induction of tumour-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes by ovarian tumour antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer", AM J OBSTET GYNECOL, vol. 183, 2000, pages 601 - 9 |
| YAP TA; CARDEN CP; KAYE SB: "Beyond chemotherapy: targeted therapies in ovarian cancer", NATURE REV CANCER, vol. 9, 2009, pages 167 - 81 |
| ZHAO X; WEI YQ; PENG ZL: "Induction of T cell responses against autologous ovarian tumours with whole tumour cell lysate-pulsed dendritic cells", IMMUNOL INVEST, vol. 30, 2001, pages 33 - 45 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017167959A1 (en) * | 2016-04-01 | 2017-10-05 | Apceth Gmbh & Co. Kg | Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy |
| JP2019509715A (en) * | 2016-04-01 | 2019-04-11 | アプセト ゲーエムベーハー アンド ツェーオー．カーゲー | Mesenchymal stem cells to enhance the antitumor activity of immunotherapy |
| EP3730607A1 (en) | 2016-04-01 | 2020-10-28 | Apceth GmbH & Co. KG | Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150306145A1 (en) | 2015-10-29 |
| US10022402B2 (en) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6207783B2 (en) | Method for the proliferation of antigen-specific T cells | |
| JP5816627B2 (en) | Method for the proliferation of antigen-specific T cells | |
| Hernando et al. | Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial | |
| Stift et al. | Dendritic cell-based vaccination in solid cancer | |
| KR101419711B1 (en) | Method for activation treatment of antigen-presenting cell | |
| JP7282874B2 (en) | Exosome-based anti-tumor vaccine | |
| JP5986196B2 (en) | Means and methods for active cell carcinoma immunotherapy using tumor cells and dendritic cells killed by high hydrostatic pressure | |
| US20200071668A1 (en) | Exosome for stimulating t cell and pharmaceutical use thereof | |
| US20120107294A1 (en) | Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umblical cord blood | |
| US20220000930A1 (en) | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same | |
| US8673296B2 (en) | Method and composition for producing a cellular allogeneic vaccine | |
| JP6235085B2 (en) | Means and methods for active cell carcinoma immunotherapy using tumor cells and dendritic cells killed by high hydrostatic pressure | |
| Pham et al. | Tracking the migration of dendritic cells by in vivo optical imaging | |
| US10022402B2 (en) | Allogenic mesendritic vector for ovarian cancer | |
| Clark et al. | Ultrastructural basis of enhanced antitumor cytotoxicity of cord blood-derived CTLs: a comparative analysis with peripheral blood and bone marrow | |
| Vichchatorn et al. | Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme | |
| US20060073589A1 (en) | Rapid generation of activated mononuclear antigen presenting cells from monocytes | |
| Salem et al. | Synergistic combination of murine bone marrow-derived dendritic cells loaded ex vivo with whole tumor lysate and systemic chemotherapy mediates antitumor immune responses in vivo | |
| US20220378872A1 (en) | Composition for treatment and/or prevention of tumor | |
| US20230149523A1 (en) | Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells | |
| Shojaeefar et al. | Dendritic Cell-Based Cancer Immunotherapy | |
| CN115927200A (en) | Dendritic cell vaccine targeting receptor HER2 | |
| JP5084012B2 (en) | Idiotype antigen carrier and idiotype vaccine using the same | |
| JP2021526826A (en) | Virus detection assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13820873 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14649212 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13820873 Country of ref document: EP Kind code of ref document: A1 |